A Study of JNJ-87704916, as Monotherapy and in Combination for Advanced Solid Tumors
Recruiting now · Phase 1
Conditions studied: Neoplasms
In brief
The purpose of this study is to determine the safety, feasibility, recommended dose(s) and regimen(s) of JNJ-87704916 as monotherapy and in combination with cetrelimab.
Key facts
- Study ID
- NCT06311578
- Run by
- Johnson & Johnson Enterprise Innovation Inc.
- People needed
- 126
- Starts
- 2024-04-10
- Expected to finish
- 2033-02-14
- Last updated by the study team
- 2026-07-06
Who can join
Age: 18 and older. Sex: any. Healthy volunteers: not accepted.
You may qualify if…
- For Part 1: Individuals with a diagnosis of advanced or metastatic solid tumor exhausting all available standard of care therapy; Part 2: Individuals with histologically or cytologically confirmed metastatic or locally advanced NSCLC
- Have at least 1 injectable tumor
- Eastern cooperative oncology group (ECOG) performance status of grade 0 or 1
- A participant who can have children must have a negative pregnancy test before the first dose of study treatment and during the study
- Thyroid function laboratory values within normal range except for participants on thyroid hormone replacement therapy
You may not qualify if…
- Active disease involvement of the CNS (example, primary central nervous system tumors, metastases, leptomeningeal disease). Some exceptions are allowed
- Prior history of, or active, significant herpetic infections (example, herpetic keratitis or encephalitis) or active herpetic infections that require ongoing systemic anti-viral therapy
- Active infection or condition that requires treatment with systemic anti-infective agents (example, antibiotics, antifungals, or antivirals) within 7 days prior to the first dose of study treatment or chronic use of anti-infective agents
- History of solid organ or hematologic stem cell transplantation
- Known positive test result for human immunodeficiency virus (HIV) or other immunodeficiency syndrome
- History of allergy to protein-based therapies or history of any significant drug allergy (such as anaphylaxis, hepatotoxicity, or immune-mediated thrombocytopenia or anemia)
Where it is running
- Hosp Univ Hm Sanchinarro — Madrid, Spain (enrolling)
- NYU Langone Health — New York, New York, United States (enrolling)
- UPMC Cancer Centers — Pittsburgh, Pennsylvania, United States (enrolling)
- MD Anderson Cancer Center — Houston, Texas, United States (enrolling)
- Toronto General Hospital — Toronto, Ontario, Canada (enrolling)
- Centre Hospitalier de l'Universite de Montreal — Montreal, Quebec, Canada (enrolling)
- Gustave Roussy — Villejuif, France (enrolling)
- Hosp Univ Vall D Hebron — Barcelona, Spain (enrolling)
- Hosp Univ Fund Jimenez Diaz — Madrid, Spain (enrolling)
- Fox Chase Cancer Center — Philadelphia, Pennsylvania, United States
Full record on ClinicalTrials.gov
Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.